Skip to content

Erythropoietin in perinatal asphyxia

Erythropoietin monotherapy for prevention of mortality after moderate to severe hypoxic ischemic encephalopathy in term neonates in low resource setting- a feasibility study in SMS Medical College

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/06/053547
Enrollment
272
Registered
2023-06-05
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: P916- Hypoxic ischemic encephalopathy [HIE]

Interventions

Intervention1: intravenous erythropoeitin: i.v erythropoeitin 1000 IU/kg on alternate days for initial 10 days of life Control Intervention1: Standard routine care: Neonate will receive the same stand

Sponsors

Sawai man singh medical college and attached hospitals
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: For inborns 1) Age = 36 weeks (based on reported last menstrual period or ultrasound) 2) Need for continued resuscitation at 5 min of age and/or 5-min Apgar score 3) Evidence of moderate or severe encephalopathy at For outborns 1) Age = 36 weeks (based on reported last menstrual period or ultrasound) 2) Lack of crying by 5 min of age 3) Evidence of moderate or severe encephalopathy at < 24 h of age on a structured clinical examination based on modified Sarnat staging

Exclusion criteria

Exclusion criteria: 1) Neonates with congenital anomalies, chromosomal abnormalities, congenital infections, severe intrauterine growth retardation and inborn errors of metabolism 2) Imminent death of the newborn before enrolment

Design outcomes

Primary

MeasureTime frame
To compare the mortality rates in neonates with moderate to severe HIE among neonates who receive erythropoietin and routine supportive care with those who receive only routine supportive careTimepoint: From NICU admission till discharge or death

Secondary

MeasureTime frame
To evaluate adverse events of EPO administrationTimepoint: From NICU admission till discharge or death;To evaluate Hammersmith infant neurological examination (HINE) on follow up at 3-6 months of ageTimepoint: 3-6 months of age;To evaluate the severity of brain injury on the basis of a standard score on conventional magnetic resonance imagingTimepoint: At the time of hospital discharge and on follow up

Countries

India

Contacts

Public ContactDr Ramesh Choudhary

Sawai Man Singh Medical College and attached hospitals Jaipur

drakash.jpr@gmail.com9887248273

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026